Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390952 | 0.88 | BDKRB2 (0.45) | BDKRB2NAMPTIGF1RDHODHKMT2A | |
| SCHEMBL6386312 | 0.86 | EPHX1 (0.42) | BDKRB2DHODHMEN1KMT2A | |
| SCHEMBL6385697 | 0.85 | BDKRB2 (0.41) | BDKRB2IGF1RDHODHSIGMAR1MEN1 | |
| SCHEMBL6385642 | 0.85 | DRD2 (0.44) | BDKRB2MEN1KMT2A | |
| SCHEMBL6387921 | 0.85 | BDKRB2 (0.51) | BDKRB2IGF1RDHODHTMEM97SIGMAR1 | |
| SCHEMBL6385497 | 0.83 | HTR2C (0.51) | BDKRB2DHODH | |
| SCHEMBL6388920 | 0.83 | HTR2C (0.50) | BDKRB2DHODH | |
| SCHEMBL6385253 | 0.82 | CACNA1G (0.48) | NPC1RAB9A | |
| SCHEMBL6391450 | 0.82 | HTR2C (0.42) | BDKRB2DHODH | |
| SCHEMBL4698590 | 0.81 | BDKRB2 (0.40) | BDKRB2TMEM97SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | BDKRB2 73/4885NAMPT 2891/4885IGF1R 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.